{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"2.550","rs_stock_flag":false,"fiscal_year_end":"2024年12月31日","hist_closedate":"2025年9月25日","replication_method":null,"amt_os":"2,128,434,305","primaryexch":"香港交易所","ric":"1873.HK","product_subtype":null,"db_updatetime":"2025年9月28日08:06","mkt_cap_u":"B","am_u":"M","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":0.0783,"inline_upper_strike_price":"","sedol":"BJBL0L5","am":"25.15","iv":"","ew_strike":"","as":"2.410","geographic_focus":null,"incorpin":"開曼群島","etp_baseCur":null,"ew_amt_os":"","bd":"2.400","registrar":"卓佳證券登記有限公司","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"500","update_time":"2025-09-28 00:06:03.0","lo52":"0.610","shares_issued_date":"2025年8月31日","premium":"","strike_price_ccy":null,"yield":"","vo_u":"M","base_currency":null,"coupon":"","expiry_date":"","chairman":"毛晨","underlying_ric":"1873.HK","hi52":"2.930","issuer_name":"維亞生物科技控股集團","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"2025年9月26日16:08","aum_date":"","lo":"2.380","mkt_cap":"5.12","f_aum_hkd":null,"ew_sub_per_to":"","ls":"2.410","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"醫療保健業 - 藥品及生物科技","ew_desc":null,"inception_date":"","nc":"-0.150","aum":"","issued_shares_class_B":null,"vo":"10.35","secondary_listing_flag":false,"listing_date":"2019年5月9日","issued_shares_class_A":null,"as_at_label":"截至","ew_amt_os_dat":"","nm":"維亞生物科技控股集團","nm_s":"維亞生物","sym":"1873","inline_lower_strike_price":"","listing_category":"主要上市","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.010","strike_price":"","summary":"維亞生物科技控股集團是一家投資控股公司。該公司有兩個分部。藥物發現服務分部提供就臨床前創新藥物開發向生物科技及製藥客戶提供基於結構的藥物發現服務。同研發生產組織務（CDMO）及商業化服務分部從事小分子原料藥及中間體的合同研發生產服務以及買賣原料藥、中間體及製劑。該公司主要在美國、中國、歐洲和其他地區開展業務。","op":"2.550","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"生物技術","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"香港銅鑼灣<br/>希慎道33號<br/>利園一期<br/>19樓1901室","pc":"-5.86","days_to_expiry":null,"underlying_code":null,"pe":"29.11","eps_ccy":"RMB","hdr":false,"launch_date":"","hc":"2.560","isin":"KYG9390W1015","moneyness":""}},"qid":"1759074292431"}
